That WISP2 has been reported to be possibly regulated by the typical Wnt and TGF-β pathways for treatment of obesity and metabolic diseases, and developing new therapeutic strategies (Grünberg et al., 2018). The gene discussed is CCN5; the disease is Other metabolic disease.